DOAC Therapy for NVAF Patients Quiz
4 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

Which factor was significantly reduced by all DOACs in the phase III trials compared with warfarin?

  • Cardioembolic stroke
  • Thrombotic stroke
  • Ischemic stroke (correct)
  • Hemorrhagic stroke

    • In which patients should dabigatran be avoided according to the phase III trials?

  • Patients with a history of hemorrhagic stroke
  • Patients with a CHADS 2 score less than 3 (correct)
  • Patients with a CHADS 2 score of 3 or more
  • Patients with a history of ischemic stroke

    • Which of the following statements is true about the effectiveness of apixaban and rivaroxaban?

  • Apixaban was superior to warfarin in the ARISTOTLE trial (correct)
  • Rivaroxaban was significantly better than apixaban in reducing stroke risk
  • Apixaban was only noninferior to warfarin in the ARISTOTLE trial
  • Rivaroxaban was superior to warfarin in the ROCKET-AF trial

    • Which DOAC showed superiority in reducing stroke risk compared to warfarin in its respective trial?

    <p>Apixaban</p> Signup and view all the answers

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser